Director/PDMR Shareholding

RNS Number : 0319C

Ergomed plc

13 June 2019

 

Ergomed Plc

("Ergomed" or the "Company")

PDMR Dealing

Ergomed, a company focused on providing specialised services to the pharmaceutical industry, announces that on 12 June 2019, Richard Barfield, Chief Financial Officer of the Company, purchased 64,000 ordinary shares of 1 pence each in the Company ("Share(s)") at a price of 270 pence per Share (the "Purchase").

Following the Purchase, Richard Barfield's holding in the Company is 100,000 Shares (representing 0.21 per cent. of the Company's issued share capital).

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Richard Barfield
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed Plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Purchase of Shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		270 pence	64,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	Volume: 64,000 ordinary shares of 1 pence each, purchase price of 270 pence per share Aggregated: £172,800.00
f)	Date of the transaction	12 June 2019
g)	Place of the transaction	London Stock Exchange, AIM

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Mary-Jane Elliott	[e-mail]
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 

END

 

 

DSHKMGMVNZGGLZM